Castor, a Hoboken, N.J.- and Amsterdam, The Netherlands-based provider of clinical trial technology that automates the research process, raised $12m in funding.
The round was led by Two Sigma Ventures with participation from Hambrecht Ducera Growth Ventures and existing investor INKEF Capital.
The company intends to use the funds to continue to develop the platform and expand its business reach.
Led by Derk Arts, MD, PhD, CEO & Founder, Castor is a cloud-based clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for researchers globally. It’s used by more than 50,000 users across academia and commercial research, powering more than 4,000 studies with more than 2,000,000 enrolled patients across 90 countries. 192 medical device, biotech, and pharmaceutical companies and contract research organizations (CROs) are using the platform.
In 2018, the company raised $6.25M from early-stage investor INKEF Capital.